3-[(3E,6Z,9Z,28Z)-heptatriaconta-3,6,9,28-tetraen-19-yl]oxy-N,N-dimethylpropan-1-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-[(3E,6Z,9Z,28Z)-heptatriaconta-3,6,9,28-tetraen-19-yl]oxy-N,N-dimethylpropan-1-amine
• 化学式: C₄₂H₇₉NO
• 分子量: 614.1
• InChiKey: NVZNHRLWJVPSSK-PQHLKXQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.1
• 重原子数：
  44
• 可旋转键数：
  35
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF
  申请人：CureVac AG

  公开号：EP3601576A1

  公开（公告）日：2020-02-05
• [EN] STABLE NON-AGGREGATING NUCLEIC ACID LIPID PARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE PARTICULES DE LIPIDE ET D'ACIDE NUCLÉIQUE SANS AGRÉGATS ET STABLES
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2014008334A1

  公开（公告）日：2014-01-09

  The present invention relates to stable lipid nanoparticle pharmaceutical formulations which are substantially free of large aggregates (e.g., aggregates greater than 1 μm in size) and include a substantially non-ionic medium.
• [EN] DELIVERY ENHANCERS FOR CONJUGATED SIRNA AND LIPID NANOPARTICLES<br/>[FR] ACTIVATEURS D'ADMINISTRATION D'ARNSI CONJUGUÉ ET DE NANOPARTICULES LIPIDIQUES
  申请人：MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V

  公开号：WO2016079197A1

  公开（公告）日：2016-05-26

  The present invention relates to lipid nanoparticles and pharmaceutical formulations containing them that exhibit enhanced cellular delivery of active pharmaceutical ingredients such as siRNA. The present invention also relates to a process for preparing such lipid nanoparticles and pharmaceutical formulations and their use.
• [EN] NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF<br/>[FR] ACIDES NUCLÉIQUES CODANT POUR DES PROTÉINES ASSOCIÉES À CRISPR ET LEURS UTILISATIONS
  申请人：CUREVAC AG

  公开号：WO2018172556A1

  公开（公告）日：2018-09-27

  The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.